Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics, Inc. filed a Form 144 reporting intent to sell shares acquired on vesting of Restricted Stock Units. The filing lists 2,039 shares tied to RSUs vested on 03/01/2026 and 4,167 shares tied to RSUs vested on 03/03/2026.
The transactions are noted as equity compensation sales through a broker on or about those dates; the filing provides the share counts and vesting basis but does not state sale prices or proceeds.
Kymera Therapeutics reported proposed sales of common stock under a Form 144. The notice lists two batches of shares tied to restricted stock units that vested under the 2020 Equity Incentive Plan: 7,576 shares on 03/01/2026 and 5,000 shares on 03/03/2026. The shares are described as acquired upon vesting and are listed with a broker on NASDAQ.
Kymera Therapeutics, Inc. established an at-the-market stock offering program allowing it to sell up to $500,000,000 of common shares through TD Securities (USA) LLC, which will act on a best efforts basis for sales on Nasdaq and other permitted methods.
The company will pay TD Cowen a commission of up to 3.0% of gross proceeds and may start, pause, or terminate sales at its discretion. Separately, Kymera filed a resale prospectus supplement registering the potential resale by certain existing investors of up to 18,819,826 outstanding common shares and 12,565,253 shares issuable upon exercise of pre-funded warrants at an exercise price of $0.0001 per warrant. Kymera will not receive proceeds from any resale of these shares, and will receive cash only if the warrants are exercised for cash.
Kymera Therapeutics is registering for resale up to 31,385,079 shares of its common stock. This amount consists of 18,819,826 shares plus up to 12,565,253 shares issuable upon exercise of pre-funded warrants, and the registration is to permit resale by the selling stockholders.
The registration is a resale registration under a registration rights agreement; Kymera states it will not receive proceeds from secondary sales, although cash exercises of the pre-funded warrants would yield proceeds equal to the $0.0001 exercise price per share. The prospectus cites February 26, 2026 and reports the registered shares represent approximately 38% of outstanding shares as of February 20, 2026.
Kymera Therapeutics filed a prospectus supplement to sell up to $500,000,000 of common stock in an at-the-market offering through TD Securities (USA) LLC (TD Cowen).
The prospectus states TD Cowen will act as sales agent and may sell shares in negotiated transactions, block trades or on Nasdaq, with compensation up to 3.0% of gross proceeds. The document uses an illustrative price of $91.01 per share (last reported sale price on February 24, 2026) and assumes 5,493,901 shares for illustrative proceeds of $500.0 million. Shares outstanding were 81,323,532 as of December 31, 2025. The company states proceeds, if any, would be used to fund research and clinical development, and for working capital and general corporate purposes.
Kymera Therapeutics files its annual report describing a clinical-stage pipeline built around targeted protein degradation, aiming to create oral small‑molecule medicines with biologics‑like efficacy. The company focuses mainly on immunology, targeting large populations with Type 2 and autoimmune diseases that remain poorly served by current therapies.
Lead STAT6 degrader KT-621 has completed Phase 1 studies and a Phase 1b atopic dermatitis trial, showing deep STAT6 degradation, broad Type 2 biomarker reductions and meaningful improvements in skin scores and itch, supporting ongoing Phase 2b trials in atopic dermatitis and asthma. IRF5 degrader KT-579 has entered Phase 1 after preclinical data showing potent, selective degradation and strong activity in lupus and arthritis models.
The report highlights collaborations: with Sanofi on IRAK4 degraders, where Kymera has received multiple milestones and Sanofi plans clinical testing of KT‑485/SAR447971 in 2026, and with Gilead on CDK2 molecular glue degraders in oncology, including a $40 million upfront payment and future milestone and royalty potential. Kymera details an extensive patent estate around its ligase ligands, degraders and targets, and notes reliance on third‑party manufacturers and contract research partners, along with substantial ongoing funding needs and typical biotech risks.
Kymera Therapeutics reported fourth-quarter and full-year 2025 results alongside a broad pipeline update. Collaboration revenue for 2025 was $39.2 million, down from $47.1 million in 2024, while higher R&D spending of $316.6 million and G&A of $68.2 million drove a wider annual net loss of $311.4 million versus $223.9 million a year earlier.
The company significantly strengthened its balance sheet by completing an underwritten equity offering with total gross proceeds of approximately $692 million, ending 2025 with about $1.6 billion in cash, cash equivalents and investments and projecting a cash runway into 2029.
Kymera highlighted progress for its KT-621 STAT6 degrader, including positive Phase 1b atopic dermatitis data, FDA Fast Track designation, and ongoing Phase 2b BROADEN2 (AD) and BREADTH (asthma) trials. It also began first-in-human dosing for KT-579, an IRF5 degrader in Phase 1, advanced partnered IRAK4 and CDK2 programs, and appointed experienced developer Neil Graham as Chief Development Officer.
Kymera Therapeutics CEO Nello Mainolfi reported a combination of option exercises and share sales on 2026-02-25. He exercised stock options for 30,000 shares at an exercise price of $2.08 per share, converting a derivative award into common stock.
On the same day he sold a total of 30,000 shares of common stock in open-market transactions at weighted average prices within disclosed ranges between $89.16 and $93.15 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated September 6, 2024. After these transactions, he directly owned 666,195 shares of Kymera common stock.
KYMR issuer reports a proposed sale of 30,000 common shares. The Form 144 lists the 30,000-share sale as an exercise of stock options on 02/25/2026 to be sold in cash. The filing names Nello Mainolfi and also shows prior sales of 100,000 shares on 12/08/2025 and 30,000 shares on 12/31/2025.
Kymera Therapeutics director Pamela Esposito reported option exercises and share sales. She exercised stock options for 2,500 shares of common stock at $49.10 per share through a derivative conversion, from a fully vested and exercisable option grant.
On the same date, she sold 1,900 common shares at a weighted average price of $87.0579 and 600 shares at $88.10, in open-market transactions. According to the disclosure, these sales were executed under a Rule 10b5-1 trading plan dated September 17, 2025, which pre-arranges trades in advance.